Trial · NCT01950234
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Patients Exhibiting a 20% Worsening in T25FW at 36 Months | Month 36 | |
| Secondary | Safety and Tolerability of ACTH: Menstrual Changes [Female] | Month 36 | Count of participants self reporting at any time throuhgout the study noticing any changes in menstrual cycle or period. |
| Secondary | Safety and Tolerability of ACTH: DEXA Scans | Month 36 | The number is a T-score. There is no maximum or minimum value. Mean change in average of 5 DEXA scan values dual-energy x-ray absorptiometry; measures bone mineral density. Higher numbers are better. A DEXA T-score has a mean of 0 and standard deviation of 1, meaning that a T-score represents how many standard deviations a person's bone density is away from the average bone density of a healthy young adult, with a score of 0 indicating average bone density. Higher scores are better, indicating better bone density. A T-score of -1 to +1 is considered normal bone density, a score between -1 and -2.5 indicates osteopenia (low bone mass), and a score of -2.5 or lower indicates osteoporosis. |
| Secondary | Safety and Tolerability of ACTH: Bruising | Month 36 | Count of participants self reporting at any time throuhgout the study that they bruise more easily |
| Secondary | Safety and Tolerability of ACTH: Swelling Ankles | Month 36 | Count of participants self reporting at any time throuhgout the study that have noticed swelling in their ankles |
| Secondary | Safety and Tolerability of ACTH: Hair Loss | Month 36 | Count of participants self reporting at any time throuhgout the study that have noticed losing more hair |
| Secondary | Safety and Tolerability of ACTH: Acne | Month 36 | Count of participants self reporting at any time throuhgout the study that have noticed in increase in acne |
| Secondary | Safety and Tolerability of ACTH: Insomnia | Month 36 | Count of participants self reporting at any time throuhgout the study that they have been having trouble sleeping |
| Secondary | Safety and Tolerability of ACTH: Mood Change | Month 36 | Count of participants self reporting at any time throuhgout the study that they have noticed changes in mood |
| Secondary | Safety and Tolerability of ACTH: GI Upset | Month 36 | Count of participants self reporting at any time throuhgout the study that they have had upset stomach, indigestion, diarrhea, or bloating |
| Secondary | Safety and Tolerability of ACTH: Fatigue | Month 36 | Count of participants self reporting at any time throuhgout the study that noticed feeling tired or worn out |
| Secondary | Safety and Tolerability of ACTH: Unpleasant Taste | Month 36 | Count of participants self reporting at any time throuhgout the study noticing a metallic taste in their mouth |
| Secondary | Safety and Tolerability of ACTH: Blurred Vision | Month 36 | Count of participants self reporting at any time throuhgout the study noticing any blurred vision |
| Secondary | Safety and Tolerability of ACTH: Moon Facies | Month 36 | New physician assessed moon facies over study duration |
| Secondary | Safety and Tolerability of ACTH: Skin Thinning | Month 36 | New physician assessed skin thinning over study duration |
| Secondary | Safety and Tolerability of ACTH: Hirsuitism | Month 36 | New physician assessed hirsuitism over study duration |
| Secondary | Safety and Tolerability of ACTH: Bruising | Month 36 | New physician assessed bruising over study duration |
| Secondary | Safety and Tolerability of ACTH: Ankle Swelling | Month 36 | New physician assessed ankle swelling over study duration |
| Secondary | Safety and Tolerability of ACTH: Hair Loss | Month 36 | Any new physician assessed hair loss over study duration |
| Secondary | Safety and Tolerability of ACTH: Cataracts | Month 36 | New physician assessed cataracts over study duration |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01950234/registered